CajanineCAS# 87402-84-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 87402-84-4 | SDF | Download SDF |
PubChem ID | 9819225 | Appearance | Powder |
Formula | C21H22O4 | M.Wt | 338.4 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)-6-[(E)-2-phenylethenyl]benzoic acid | ||
SMILES | CC(=CCC1=C(C=C(C(=C1O)C(=O)O)C=CC2=CC=CC=C2)OC)C | ||
Standard InChIKey | XPDYDSQPCFQSLH-ZHACJKMWSA-N | ||
Standard InChI | InChI=1S/C21H22O4/c1-14(2)9-12-17-18(25-3)13-16(19(20(17)22)21(23)24)11-10-15-7-5-4-6-8-15/h4-11,13,22H,12H2,1-3H3,(H,23,24)/b11-10+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Cajanine Dilution Calculator
Cajanine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9551 mL | 14.7754 mL | 29.5508 mL | 59.1017 mL | 73.8771 mL |
5 mM | 0.591 mL | 2.9551 mL | 5.9102 mL | 11.8203 mL | 14.7754 mL |
10 mM | 0.2955 mL | 1.4775 mL | 2.9551 mL | 5.9102 mL | 7.3877 mL |
50 mM | 0.0591 mL | 0.2955 mL | 0.591 mL | 1.182 mL | 1.4775 mL |
100 mM | 0.0296 mL | 0.1478 mL | 0.2955 mL | 0.591 mL | 0.7388 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-Methoxybenzoylacetic acid
Catalog No.:BCN0814
CAS No.:13422-77-0
- Elgonica dimer A
Catalog No.:BCN0813
CAS No.:132210-48-1
- Rhusflavanone
Catalog No.:BCN0811
CAS No.:53060-72-3
- Agathisflavone
Catalog No.:BCN0810
CAS No.:28441-98-7
- Roburin E
Catalog No.:BCN0809
CAS No.:137343-79-4
- Roburin D
Catalog No.:BCN0808
CAS No.:136199-93-4
- Roburin C
Catalog No.:BCN0807
CAS No.:137490-45-0
- Roburin B
Catalog No.:BCN0806
CAS No.:137370-65-1
- Roburin A
Catalog No.:BCN0805
CAS No.:132864-75-6
- Gambogoic acid A
Catalog No.:BCN0804
CAS No.:8879-23-49-1
- Moreollic acid
Catalog No.:BCN0803
CAS No.:173792-68-2
- Epigambogellic acid
Catalog No.:BCN0802
CAS No.:1352191-85-5
- Senkyunolide N
Catalog No.:BCN0816
CAS No.:140694-58-2
- Dehydrodicatechin A
Catalog No.:BCN0817
CAS No.:36048-23-4
- Barbaloin-related compound A
Catalog No.:BCN0818
CAS No.:473225-21-7
- Barbaloin-related compound B
Catalog No.:BCN0819
CAS No.:473225-22-8
- 3beta-(alpha-L-Arabinopyranosyloxy)urs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN0820
CAS No.:435269-07-1
- 3beta-Hydroxyurs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN0821
CAS No.:434942-42-4
- 10-Methoxygambogenic acid
Catalog No.:BCN0822
CAS No.:2095102-72-8
- 10-Hydroxyaloin B
Catalog No.:BCN0823
CAS No.:134863-92-6
- Gambogic acid A
Catalog No.:BCN0824
CAS No.:1592842-93-7
- 10-Carboxyloganin
Catalog No.:BCN0825
CAS No.:182172-02-7
- Oblonganoside D
Catalog No.:BCN0826
CAS No.:943021-91-8
- Cannabisin P
Catalog No.:BCN0827
CAS No.:2756983-19-2
The cajanine derivative LJ101019C regulates the proliferation and enhances the activity of NK cells via Kv1.3 channel-driven activation of the AKT/mTOR pathway.[Pubmed:31790901]
Phytomedicine. 2020 Jan;66:153113.
BACKGROUND: Natural killer (NK) cells play important roles in immune responses and have been wildly used in immunotherapy. Nevertheless, some limitations remain. It is urgent to explore novel and safe strategies to enhance NK cell activity. PURPOSE: The aim of this study was to investigate the immuno-stimulatory effects and to reveal the molecular mechanism of LJ101019C, a derivative of a natural small-molecule compounds Cajanine, on NK cells. METHODS: Cell proliferation was examined by CCK8 assay, then we used the cytotoxicity detection kit to detect the cytotoxicity of NK cells. The change of cell cycle, intracellular reactive oxygen species (ROS) level and mitochondrial mass were evaluated by FACS and Operetta high-content image analysis, respectively. Furthermore, the IFN-gamma secretion of NK cells were measured by ELISA. The Kv1.3 protein expression and function were detected by western blot and patch-clamp technique, respectively. The role of Kv1.3 in AKT/mTOR pathway activation was determined by western blot. RESULTS: The results showed that LJ101019C at relatively low concentrations (0.05-0.1microM) significantly increased the proliferation of NK cells. And 1microM LJ101019C could elevate the proportion of NK cells in the S-phase of the cell cycle (*p < 0.1). Furthermore, the cytotoxic effects of NK cells targeting MIA PaCa-2 cells were significantly enhanced by 0.1 and 1microM LJ101019C, and were associated with the enhanced secretion of IFN-gamma by NK cells (*p < 0.1; **p < 0.05). 0.1 and 1microM LJ101019C increased intracellular levels of ROS (**p < 0.05), and 0.1microM LJ101019C elevated mitochondrial mass (*p < 0.1). Electrophysiological recordings indicated that LJ101019C led to a remarkably increase the Kv1.3 current density. Moreover, western blot results indicated that LJ101019C elevated Kv1.3 protein expression and activated AKT/mTOR signaling via increasing the expression of Kv1.3 in NK cells. CONCLUSION: LJ101019C increases the proliferation and the cytotoxicity of NK cells at relatively low concentrations. The mechanism is the activation of AKT/mTOR signaling pathway driven by up-regulation of Kv1.3 in NK cells. These suggest LJ101019C is a promising candidate for improving the efficacy of NK cell-based immunotherapies.
Cajanine promotes osteogenic differentiation and proliferation of human bone marrow mesenchymal stem cells.[Pubmed:30141283]
Adv Clin Exp Med. 2019 Jan;28(1):45-50.
BACKGROUND: Seed cells - mesenchymal stem cells (MSCs) - appear to be an attractive tool in the context of tissue engineering. Bone marrow represents the main source of MSCs for both experimental and clinical studies. However, the number limitation of bone marrow MSCs (BMSCs) and decreased function caused by proliferation make the search for adequate alternative sources of these cells for autologous and allogenic transplant necessary. OBJECTIVES: This study was aimed to investigate the roles of Cajanine isolated from the extracts of Cajanus cajan L. Millsp. in the proliferation and differentiation of BMSCs, and to discover the mechanism of proliferation of BMSCs promoted by Cajanine. MATERIAL AND METHODS: Bone marrow mesenchymal stem cells were cultured in high-glucose Dulbecco's Modified Eagle's Medium (DMEM) and osteogenic differentiation was induced by adding dexamethasone, ascorbic acid and beta-glycerophosphate supplements. Bone marrow MSCs were cultured in medium without Cajanine or supplemented with Cajanine. The information about the proliferation and osteogenic differentiation of BMSCs was collated. The osteogenic differentiation potential of BMSCs was also assessed at the 3rd passage by Von Kossa staining. To observe cell signal transduction changes of BMSCs after culturing them with Cajanine for 24 h, the western blot analysis was performed to detect phosphorylated cell cycle proteins and activated cyclins. RESULTS: After osteogenic induction, the differentiation of BMSCs was accelerated by Cajanine treatment. Osteogenesis markers were upregulated by Cajanine treatment at both protein and mRNA levels. Cajanine obviously promoted the proliferation of BMSCs. After BMSCs were cultured with Cajanine for 24 h, the cell cycle regulator proteins were phosphorylated or upregulated. CONCLUSIONS: Cajanine can promote the expansion efficiency of BMSCs, at the same time keeping their multi-differentiation potential. Cajanine can activate the cell cycle signal transduction pathway, thus inducing cells to enter the G1/S phase and accelerating cells entering the G2/M phase. This study can contribute to the development of Cajanine-based drugs in tissue engineering.
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.[Pubmed:27783522]
J Med Chem. 2016 Nov 23;59(22):10268-10284.
There still remains a need to develop new anti-HCV agents with distinct mechanism of action (MOA) due to the occurrence of resistance to direct-acting antiviral agents (DAAs). Cajanine, a stilbenic component isolated from Cajanus cajan L., was identified as a potent HCV inhibitor by phenotypic screening in this work (EC50 = 3.17 +/- 0.75 muM). The intensive structure optimization provided significant insights into the structure-activity relationships. Furthermore, the MOA study revealed that Cajanine inhibited HCV replications via down-regulating a cellular protein chondroitin sulfate N-acetylgalactosaminyltransferase 1. In consistency with this host-targeting mechanism, Cajanine showed the similar magnitude of inhibitory activity against both drug-resistant and wild-type HCV and synergistically inhibited HCV replication with approved DAAs. Taken together, our study not only presented Cajanine derivatives as a novel class of anti-HCV agents but also discovered a promising anti-HCV target to combat drug resistance.
(E)-2-Hy-droxy-4-meth-oxy-3-(3-methyl-but-2-en-yl)-6-styryl-benzoic acid.[Pubmed:23476472]
Acta Crystallogr Sect E Struct Rep Online. 2013 Jan 1;69(Pt 1):o91.
The title compound, C21H22O4, also known as Cajanine, features an intra-molecular O-Hcdots, three dots, centeredO hydrogen bond between the adjacent carb-oxy and hy-droxy groups. The benzene rings make an inter-planar angle of 175.4 (2) degrees . In the crystal, mol-ecules are linked by pairs of O-Hcdots, three dots, centeredO hydrogen bonds, forming inversion dimers.
[Effects of the extracts of Cajanus cajan L. on cell functions in human osteoblast-like TE85 cells and the derivation of osteoclast-like cells].[Pubmed:17633205]
Yao Xue Xue Bao. 2007 Apr;42(4):386-91.
The Cajanine (longistylin A-2-carboxylic acid) is isolated and identified from extracts of Cajanus cajan L. (ECC) , which structure is similar to diethylstilbestrol. The regulation properties of the Cajanine and other four extracts of Cajanus cajan L. (32-1, 35-1, 35-2, and 35-3) were tested in human osteoblast-like (HOS) TE85 cells and marrow-derived osteoclast-like cells. By using MTT assay to test the change of cell proliferation, 3H-proline incorporation to investigate the formation of collagen, and by measuring alkaline phosphatase (ALP) activity, bone formation in HOS TE85 cell was evaluated after pretreated for 48 hours. Bone marrow cells were cultured to examine the derivation of osteoclast cells (OLCs), which were stained with tartrate-resistant acid phosphatase (TRAP). The long term effect (pretreated for 18 days) on promoting mineralized bone-like tissue formation was tested by Alizarin red S staining in HOS TE85 cells. After the treatment with Cajanine (1 x 10(-8) g x mL(-1)) for 48 hours, cell number increased significantly (57.7%). 3H-Proline incorporation also statistically increased (98.5%) in those cells. Significant change of ALP activity was also found (P < 0.01) in 35-1 and 35-3 treated cells (they were 66.2% and 82.4% in the concentration of 1 x 10(-8) g x mL(-1), respectively). The long term (18 days) effects of 32-1 and 35-3 on promoting mineralized bone-like tissue formation in HOS TE85 cell were obvious. There were much more red blots over the field of vision compared with that of control group. After the treatment of Cajanine, derived-osteoclast cells appeared later and much less compared with control. The inhibition of Cajanine was 22.8% while it was 37.9% in 32-1 treated cells in the dose of 1 x 10(-7) g x mL(-1). It is obvious that Cajanine and ECCs promoted the osteoblast cells proliferation and mineralized bone-like tissue formation in HOS TE85 cells, while inhibited derivation of osteoclast cells. All of these suggested that Cajanine has the estrogen-like action on osteoblast and osteoclast, which could be developed as anti-osteoporosis drugs.